


SARCLISA[®]
(isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL


SARCLISA ESCENA[™] FOR USE WITH
(isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL


On-Body Delivery System

SARCLISA ESCENA[™] (isatuximab-irfc) **with CirCLIQ[™]** and **SARCLISA[®]** (isatuximab-irfc) **Billing and Coding Guide**

Your guide to access and reimbursement

The information provided in this reimbursement guide is valid as of July 2026 and is subject to change.

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.

Introduction

This guide provides billing, coding, and reimbursement information for SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™ and SARCLISA (isatuximab-irfc). It also includes sample forms, a list of specialty distributors and wholesalers, and information about patient support and reimbursement.

Please note:

- While the information in this guide is current as of the date of publication, it is subject to change without notice
- This guide is provided for informational purposes only and does not constitute legal or reimbursement advice. It is not intended to substitute for the physician’s independent diagnosis or treatment of each patient. The information contained herein is gathered from various resources and is subject to change. Providers are solely responsible for the accuracy of all coding and claims submitted for reimbursement to any third-party payor

Indications for SARCLISA (isatuximab-irfc) and SARCLISA ESCENA (isatuximab-irfc)

- SARCLISA and SARCLISA ESCENA are indicated in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)
- SARCLISA and SARCLISA ESCENA are indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy
- SARCLISA is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor
- SARCLISA ESCENA is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor

Important Safety Information for SARCLISA and SARCLISA ESCENA

CONTRAINDICATIONS—SARCLISA and SARCLISA ESCENA

SARCLISA and SARCLISA ESCENA are contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients.

Table of contents

Coding and reimbursement for SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™

NDC numbers

ICD-10-CM codes

HCPCS codes

CPT® codes

Revenue codes

Place of service codes

4

4

4

5

5

5

Sample claim forms for SARCLISA ESCENA™ with CirCLIQ™

CMS-1500 form

CMS-1450 (UB-04) form

7

9

Dosing and Administration information for SARCLISA ESCENA™ with CirCLIQ™

10

Coding and reimbursement for SARCLISA (isatuximab-irfc)

NDC numbers

ICD-10-CM codes

HCPCS codes

CPT® codes

Revenue codes

Place of service codes

12

12

12

13

13

13

Sample claim forms for SARCLISA

CMS-1500 form

CMS-1450 (UB-04) form

14

17

Dosing and Administration information for SARCLISA

18

Ordering and distribution

Specialty pharmacies and distributors

Product returns

20

20

Patient support

21

Important Safety Information

22



Billing and coding for SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™*

The billing and coding information is for your reference only and is subject to change. Please be sure to consult your organization for reimbursement, billing, and coding guidance. Note, these codes are relevant for SARCLISA ESCENA with or without CirCLIQ.

NDC numbers ¹		
10-digit NDC	11-digit NDC [†]	Description
0024-0674-01	00024-0674-01	1,400 mg/10 mL single-dose vial

*These codes are not intended to encourage or suggest a use of the drug that is inconsistent with FDA-approved use. The codes are not intended to be exhaustive, and additional codes may apply. Payer policies for billing and coding vary. Consult your payers for guidance.
[†]Payer requirements for 10- or 11-digit NDC use and format may vary. Please verify requirements prior to use.

ICD-10-CM diagnosis codes ²	
Code	Description
C90.OX	Multiple myeloma
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse

HCPCS code ³			
HCPCS code	Description	HCPCS code dosage (billing units)	Example
J3590	Unclassified biologics	10 mg = 1 unit	1,400-mg vial = 140 units

Sanofi anticipates the permanent HCPCS code to be available in April 2027.

CPT® code ⁴	
Code	Description
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

Revenue codes (for hospital outpatient departments) ⁵	
Code	Description
0331	Chemotherapy administration–injection
0636	Drugs requiring detailed coding

Place of service codes ⁶		
Code	Name	Description
11	Office	Location, other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF), where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.
19	Off Campus–Outpatient Hospital	A portion of an off-campus hospital provider based department which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization (Effective January 1, 2016).
22	On Campus–Outpatient Hospital	A portion of a hospital’s main campus which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization (Description change effective January 1, 2016).

CPT, Current Procedural Terminology; FDA, US Food and Drug Administration; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA

Infusion-Related Reactions—SARCLISA

SARCLISA can cause severe and/or serious infusion-related reactions including anaphylactic reactions. These reactions can be life-threatening and fatal outcomes have been reported. Severe signs and symptoms include cardiac arrest, hypertension, hypotension, bronchospasm, dyspnea, angioedema, and swelling.

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.


SARCLISA ESCENA™
(isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL


FOR USE WITH
On-Body Delivery System

CMS sample forms for SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™

This CMS sample form is provided as an example. This CMS-1500 form is commonly used for billing for prescribed medications administered in healthcare provider (physician) offices.

The notes below provide information about how to populate the essential fields that health plans require for reimbursement. (For medication administered in hospital outpatient settings, please see pages 8 and 9.)

This sample claim form is intended for use only as a reference. Reimbursement codes are subject to continual change. Please confirm the accuracy of the codes you use to bill for the prescribed medications with each payer.

Item 21

Enter the appropriate ICD-10-CM diagnosis codes for multiple myeloma

Item 24A

Enter the date of service for each procedure, service, or supply. Include NDC information, if required, in the shaded areas above each date

Item 24D

Enter J-code [J3590] and appropriate CPT codes and modifiers for procedures, services, and supplies. Enter the specific procedure code without a description. If you need to report an “unlisted procedure” code or a “not otherwise classified” (NOC) code, include a detailed description in Box 19

Item 24E

Enter the diagnosis code reference letter or number from Box 21 that relates to the date of service and the services or procedures performed that are entered on that same line under 24D

Item 24G

Enter the appropriate number of billing units based on the HCPCS code dosage of 1,400 mg. For example, 1,400 mg = 140 billing units

CMS-1500 sample7 Physician office form

HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE MEDICAID TRICARE CHAMPVA GROUP HEALTH PLAN FECA BLK LUNG OTHER

2. PATIENT'S NAME (Last Name, First Name, Middle Initial) Doe, John

3. PATIENT'S BIRTH DATE 03 | 09 | 49 M F

4. INSURED'S NAME (Last Name, First Name, Middle Initial) Doe, John

5. PATIENT'S ADDRESS (No., Street) 123 Main St.

6. PATIENT RELATIONSHIP TO INSURED Spouse

7. INSURED'S ADDRESS (No., Street)

8. CITY New York

9. ZIP CODE 10001

10. TELEPHONE (Include Area Code) (212) 555-6789

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE

14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP)

15. OTHER DATE

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE

18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

20. OUTSIDE LAB?

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY

22. RESUBMISSION CODE

23. PRIOR AUTHORIZATION NUMBER

24. A. DATE(S) OF SERVICE 10 | 01 | 20 10 | 01 | 20

25. FEDERAL TAX I.D. NUMBER

26. PATIENT'S ACCOUNT NO.

27. ACCEPT ASSIGNMENT?

28. TOTAL CHARGE

29. AMOUNT PAID

30. REV'D FOR NUCC USE

31. SIGNATURE OF PHYSICIAN OR SUPPLIER

32. SERVICE FACILITY LOCATION INFORMATION

33. BILLING PROVIDER INFO & PH #

Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA (cont'd)

Infusion-Related Reactions—SARCLISA (cont'd)

In clinical trials (ICARIA-MM, IKEMA, and IMROZ), in patients treated with SARCLISA (N=592), infusion-related reactions occurred in 206 patients (35%). Among these 206 patients, 92% experienced infusion-related reactions during the first infusion and 12% after the first cycle.

The most common symptoms (≥5%) of an infusion-related reaction included dyspnea and cough. Grade 1 infusion-related reactions were reported in 6% of patients, grade 2 in 28%, and grade 3 or 4 in 1.2%. Anaphylactic reactions occurred in less than 1% of patients. The total incidence of SARCLISA infusion interruptions was less than 1% and the incidence of patients with at least one SARCLISA infusion interruption due to infusion-related reactions was 26%. The median time to first SARCLISA infusion interruption was 61 minutes (range 4 to 240 minutes). SARCLISA was discontinued in 1% of patients due to infusion-related reactions. To decrease the risk and severity of IRRs, premedicate patients prior to SARCLISA infusion with acetaminophen, H₂ antagonists, diphenhydramine or equivalent, and dexamethasone.

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.

Your partners in navigating patient access and reimbursement

Our Case Managers are experts in navigating the oncology space. They'll provide the information you need to get your patients started on SARCLISA ESCENA and SARCLISA IV as quickly as possible.



CMS, Centers for Medicare & Medicaid Services; CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

CMS sample forms for SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™ (cont'd)

The CMS UB-04 form is used for billing for prescribed medications administered in hospital outpatient settings. The notes below provide information about how to populate the essential fields that health plans require for reimbursement.

This sample claim form is intended for use only as a reference. Reimbursement codes are subject to continual change. Please confirm the accuracy of the codes you use to bill for the prescribed medications with each payer.

Form Locator (FL) 42

Enter the 4-digit revenue code that best describes the service provided, in accordance with hospital billing policy

FL 43

Enter the description of service (eg, SC therapy)

FL 44

Enter J-code [J3590] and appropriate CPT codes

FL 46

Enter the appropriate number of service based on the HCPCS code dosage of 1,400 mg. For example, 1,400 mg = 140 billing units

FL 66

Enter the appropriate ICD-10-CM diagnosis codes for MM being treated

CMS-1450 (UB-04) sample⁸ Hospital outpatient form

Sample

1		2		3		4		5		6		7		8		9		10		11		12		13		14		15		16		17		18		19		20		21		22		23		24		25		26		27		28		29		30		31		32		33		34		35		36		37		38		39		40		41		42		43		44		45		46		47		48		49		50		51		52		53		54		55		56		57		58		59		60		61		62		63		64		65		66		67		68		69		70		71		72		73		74		75		76		77		78		79		80		81		82		83		84		85		86		87		88		89		90		91		92		93		94		95		96		97		98		99		100		101		102		103		104		105		106		107		108		109		110		111		112		113		114		115		116		117		118		119		120		121		122		123		124		125		126		127		128		129		130		131		132		133		134		135		136		137		138		139		140		141		142		143		144		145		146		147		148		149		150		151		152		153		154		155		156		157		158		159		160		161		162		163		164		165		166		167		168		169		170		171		172		173		174		175		176		177		178		179		180		181		182		183		184		185		186		187		188		189		190		191		192		193		194		195		196		197		198		199		200		201		202		203		204		205		206		207		208		209		210		211		212		213		214		215		216		217		218		219		220		221		222		223		224		225		226		227		228		229		230		231		232		233		234		235		236		237		238		239		240		241		242		243		244		245		246		247		248		249		250		251		252		253		254		255		256		257		258		259		260		261		262		263		264		265		266		267		268		269		270		271		272		273		274		275		276		277		278		279		280		281		282		283		284		285		286		287		288		289		290		291		292		293		294		295		296		297		298		299		300		301		302		303		304		305		306		307		308		309		310		311		312		313		314		315		316		317		318		319		320		321		322		323		324		325		326		327		328		329		330		331		332		333		334		335		336		337		338		339		340		341		342		343		344		345		346		347		348		349		350		351		352		353		354		355		356		357		358		359		360		361		362		363		364		365		366		367		368		369		370		371		372		373		374		375		376		377		378		379		380		381		382		383		384		385		386		387		388		389		390		391		392		393		394		395		396		397		398		399		400		401		402		403		404		405		406		407		408		409		410		411		412		413		414		415		416		417		418		419		420		421		422		423		424		425		426		427		428		429		430		431		432		433		434		435		436		437		438		439		440		441		442		443		444		445		446		447		448		449		450		451		452		453		454		455		456		457		458		459		460		461		462		463		464		465		466		467		468		469		470		471		472		473		474		475		476		477		478		479		480		481		482		483		484		485		486		487		488		489		490		491		492		493		494		495		496		497		498		499		500		501		502		503		504		505		506		507		508		509		510		511		512		513		514		515		516		517		518		519		520		521		522		523		524		525		526		527		528		529		530		531		532		533		534		535		536		537		538		539		540		541		542		543		544		545		546		547		548		549		550		551		552		553		554		555		556		557		558		559		560		561		562		563		564		565		566		567		568		569		570		571		572		573		574		575		576		577		578		579		580		581		582		583		584		585		586		587		588		589		590		591		592		593		594		595		596		597		598		599		600		601		602		603		604		605		606		607		608		609		610		611		612		613		614		615		616		617		618		619		620		621		622		623		624		625		626		627		628		629		630		631		632		633		634		635		636		637		638		639		640		641		642		643		644		645		646		647		648		649		650		651		652		653		654		655		656		657		658		659		660		661		662		663		664		665		666		667		668		669		670		671		672		673		674		675		676		677		678		679		680		681		682		683		684		685		686		687		688		689		690		691		692		693		694		695		696		697		698		699		700		701		702		703		704		705		706		707		708		709		710		711		712		713		714		715		716		717		718		719		720		721		722		723		724		725		726		727		728		729		730		731		732		733		734		735		736		737		738		739		740		741		742		743		744		745		746		747		748		749		750		751		752		753		754		755		756		757		758		759		760		761		762		763		764		765		766		767		768		769		770		771		772		773		774		775		776		777		778		779		780		781		782		783		784		785		786		787		788		789		790		791		792		793		794		795		796		797		798		799		800		801		802		803		804		805		806		807		808		809		810		811		812		813		814		815		816		817		818		819		820		821		822		823		824		825		826		827		828		829		830		831		832		833		834		835		836		837		838		839		840		841		842		843		844		845		846		847		848		849		850		851		852		853		854		855		856		857		858		859		860		861		862		863		864		865		866		867		868		869		870		871		872		873		874		875		876		877		878		879		880		881		882		883		884		885		886		887		888		889		890		891		892		893		894		895		896		897		898		899		900		901		902		903		904		905		906		907		908		909		910		911		912		913		914		915		916		917		918		919		920		921		922		923		924		925		926		927		928		929		930		931		932		933		934		935		936		937		938		939		940		941		942		943		944		945		946		947		948		949		950		951		952		953		954		955		956		957		958		959		960		961		962		963		964		965		966		967		968		969		970		971		972		973		974		975		976		977		978		979		980		981		982		983		984		985		986		987		988		989		990		991		992		993		994		995		996		997		998		999		1000		1001		1002		1003		1004		1005		1006		1007		1008		1009		1010		1011		1012		1013		1014		1015		1016		1017		1018		1019		1020		1021		1022		1023		1024		1025		1026		1027		1028		1029		1030		1031		1032		1033		1034		1035		1036		1037		1038		1039		1040		1041		1042		1043		1044		1045		1046		1047		1048		1049		1050		1051		1052		1053		1054		1055		1056		1057		1058		1059		1060		1061	
---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--

Dosing for SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™¹

Recommended Dosage

- **Relapsed or refractory multiple myeloma (RRMM):** 1,400 mg administered as an SC injection with the CirCLIQ OBDS or with a syringe and infusion set for manual administration, in combination with Kd or Pd
- **Newly diagnosed multiple myeloma (NDMM):** 1,400 mg administered as an SC injection with the CirCLIQ OBDS or with a syringe and infusion set for manual administration, in combination with VRd
- Treatment is repeated until disease progression or unacceptable toxicity

Dosing Schedule

RRMM schedule:

Weekly dosing transitions to every other week after the first cycle. Treatment is administered in 28-day cycles.



On the days when both SARCLISA ESCENA and carfilzomib are administered, administer dexamethasone first, followed by SARCLISA ESCENA administration, then followed by carfilzomib infusion.

NDMM schedule*:

Weekly dosing transitions to every other week after the first cycle and then to once monthly (every 4 weeks) at Cycle 13. After Cycle 13, bortezomib is stopped and patients receive triplet therapy with SARCLISA ESCENA + Rd.

Induction treatment period: 12 induction cycles, 4 weeks per cycle[†]



Continuous treatment period: 4 weeks per cycle[†]

Cycles 13 and beyond



For dosing instructions for combination agents administered with SARCLISA ESCENA, refer to the study design descriptions in the SARCLISA ESCENA Prescribing Information and the respective manufacturer's Prescribing Information.

*Pattern reflects: weekly in Cycle 1 → q2w in Cycles 2–12 → q4w (Day 1 only) from Cycle 13 onward with SARCLISA ESCENA + Rd.

[†]Induction phase and continuous phase cycles=28 days each.

Administration of SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™¹

Premedication

Administer the following premedications prior to SARCLISA ESCENA administration to reduce the risk and severity of systemic administration reactions (SARs).

Dexamethasone	When administered in combination with SARCLISA ESCENA and carfilzomib: 20 mg PO or IV When administered in combination with SARCLISA ESCENA and pomalidomide: 40 mg PO or IV (or 20 mg PO or IV for patients ≥75 years of age) When administered in combination with SARCLISA ESCENA, bortezomib, and lenalidomide: 20 mg PO
Acetaminophen	650 mg to 1,000 mg PO
Leukotriene receptor antagonists	Cycle 1 only (Days 1, 8, 15, and 22)
Diphenhydramine	25 mg to 50 mg PO or IV (or equivalent). The IV route is preferred for at least the first 4 administrations

The above recommended dose of dexamethasone (PO or IV) corresponds to the total dose to be administered before SARCLISA ESCENA administration as part of the premedication and part of the backbone treatment.

Administer the recommended premedication agents 15 to 60 minutes prior to starting a SARCLISA ESCENA administration. If no SAR occurs during Cycle 1, assess patient-specific factors and consider omitting subsequent premedication during future treatment cycles.

Preparing SARCLISA ESCENA

- SARCLISA ESCENA is a clear to slightly opalescent, colorless to slightly yellow solution that may contain a few translucent to white particles. SARCLISA ESCENA should not be used if the solution is cloudy or discolored, or if particles other than those described above are present. Inspect the vials for particulate matter and discoloration prior to administration whenever solution and container permit
- To prevent medication errors, check the SARCLISA ESCENA vial label to ensure it is the correct medication for SC use (vial with green cap)
- Prior to use, allow SARCLISA ESCENA to reach ambient temperature between 64 °F and 82 °F (18 °C and 28 °C) for approximately 20 minutes. Keep the unpunctured vial in the original carton prior to use to protect from light. Do not heat. Do not shake
- Once the vial is taken out of the refrigerator, it must not be returned to the refrigerator. Unpunctured vials may be stored at ambient temperature between 64 °F and 82 °F (18 °C and 28 °C) for a single period of up to 24 hours
- No dose reduction of SARCLISA ESCENA is recommended. Dose delay or omission may be required

IV, intravenous; Kd, carfilzomib and dexamethasone; OBDS, on-body delivery system; Pd, pomalidomide and dexamethasone; PO, by mouth; q2w, every 2 weeks; q4w, every 4 weeks; Rd, lenalidomide and dexamethasone; SC, subcutaneous; VRd, bortezomib, lenalidomide, and dexamethasone.

Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA (cont'd)

Hypersensitivity and Other Administration Reactions—SARCLISA ESCENA

SARCLISA ESCENA can cause both systemic administration reactions (SARs), including severe or life-threatening reactions, and local injection-site reactions (ISRs).

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.

Administering SARCLISA ESCENA



SARCLISA ESCENA with CirCLIQ



SARCLISA ESCENA with manual administration

- SARCLISA ESCENA is for abdominal SC administration by a healthcare provider only
- Do not administer SARCLISA ESCENA intravenously
- Change (rotate) the site of each SC administration at least 1 inch (2.5 cm) from previous injection site with every injection to avoid accumulation of fatty tissue
- Do not inject other medications in the area where SARCLISA ESCENA is injected
- Do not inject into areas where the skin is injured, tender, red, hot, has scars, or is excessively hairy
- Administer within 4 hours (including injection time) at room temperature. Discard after 4 hours if not used



Billing and coding for SARCLISA (isatuximab-irfc)*

The billing and coding information is for your reference only and is subject to change. Please be sure to consult your organization for reimbursement, billing, and coding guidance.

NDC numbers ⁹		
10-digit NDC	11-digit NDC [†]	Description
0024-0654-01	00024-0654-01	 100 mg/5 mL single-dose vial
0024-0656-01	00024-0656-01	 500 mg/25 mL single-dose vial

*These codes are not intended to encourage or suggest a use of the drug that is inconsistent with FDA-approved use. The codes are not intended to be exhaustive, and additional codes may apply. Payer policies for billing and coding vary. Consult your payers for guidance.
†Payer requirements for 10- or 11-digit NDC use and format may vary. Please verify requirements prior to use.

ICD-10-CM diagnosis codes ¹⁰	
Code	Description
C90.0X	Multiple myeloma
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse

HCPCS code ¹¹			
HCPCS code	Description	HCPCS code dosage (billing units)	Example
J9227	Injection, isatuximab-irfc, 10 mg	10 mg = 1 unit	100-mg vial = 10 units
			500-mg vial = 50 units

JW modifier: Providers and suppliers are required to report the JW modifier on Part B drug claims for discarded drugs and biologicals. Also, providers and suppliers must document the amount of discarded drugs or biologicals in Medicare beneficiaries’ medical records.

CPT [®] codes ^{12,13}	
Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary procedure)

Revenue codes (for hospital outpatient departments) ⁵	
Code	Description
0260	IV therapy
0636	Drugs requiring detailed coding

Place of service codes ⁶		
Code	Name	Description
11	Office	Location, other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF), where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.
19	Off Campus-Outpatient Hospital	A portion of an off-campus hospital provider based department which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization (Effective January 1, 2016).
22	On Campus-Outpatient Hospital	A portion of a hospital’s main campus which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization (Description change effective January 1, 2016).

CPT, Current Procedural Terminology; FDA, US Food and Drug Administration; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; IV, intravenous; NDC, National Drug Code.

Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)
WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA (cont'd)
Hypersensitivity and Other Administration Reactions—SARCLISA ESCENA (cont'd)
Systemic Administration Reactions
In a pooled safety population of 411 patients with multiple myeloma who received SARCLISA ESCENA in combination with pomalidomide and dexamethasone (Pd); carfilzomib and dexamethasone (Kd); and bortezomib, lenalidomide, and dexamethasone (VRd) (IRAKLIA, IZALCO, and IsaSocut, respectively, N=411), SARs occurred in 3.2% (Grade 1: 2.2%, Grade 2: 0.7%, Grade 3: 0.2%) of patients. SARs occurred at the first administration in 1.9% of patients and at subsequent administrations in 1.5% of patients. The median time to onset was 4 hours (range: 12 minutes to 3 days). The most frequently reported symptoms of SARs (all below 1%) were pyrexia and dyspnea, and the most frequently reported Grade ≥3 symptom was dyspnea (not collected in IsaSocut study). In multiple myeloma clinical trials with intravenous isatuximab-irfc, anaphylactic reactions occurred in <1% of patients.

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.



CMS sample forms for SARCLISA (isatuximab-irfc)

This Centers for Medicare & Medicaid Services (CMS) sample form is provided as an example. This CMS-1500 form is commonly used for billing for prescribed medications administered in healthcare provider (physician) offices.

The notes below provide information about how to populate the essential fields that health plans require for reimbursement. (For medication administered in hospital outpatient settings, please see pages 8 and 9.)

This sample claim form is intended for use only as a reference. Reimbursement codes are subject to continual change. Please confirm the accuracy of the codes you use to bill for the prescribed medications with each payer.

Item 21

Enter the appropriate ICD-10-CM diagnosis codes for multiple myeloma

Item 24A

Enter the date of service for each procedure, service, or supply. Include NDC information, if required, in the shaded areas above each date

Item 24D

Enter J-code J9227 and appropriate CPT codes and modifiers for procedures, services, and supplies. Enter the specific procedure code without a description. If you need to report an “unlisted procedure” code or a “not otherwise classified” (NOC) code, include a detailed description in Box 19

Item 24E

Enter the diagnosis code reference letter or number from Box 21 that relates to the date of service and the services or procedures performed that are entered on that same line under 24D

Item 24G

Enter the appropriate number of billing units based on the HCPCS code dosage of 10 mg. For example, 10 mg = 1 billing unit; so for a patient with multiple myeloma (MM) weighing 85 kg, the dose would be 850 mg → 85 units
JW modifier: 850 mg dose would require one 500-mg and four 100-mg vials, for a total of 900 mg, resulting in 50 mg wastage. 50 mg = 5 billing units

CMS-1500 sample⁷ Physician office form

HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE (Medicare) ☒ MEDICAID (Medicaid) ☐ TRICARE (TRICARE) ☐ CHAMPVA (CHAMPVA) ☐ GROUP HEALTH PLAN (Group Health Plan) ☒ FECA (FECA) ☐ OTHER (Other) ☐

2. PATIENT'S NAME (Last Name, First Name, Middle Initial) Doe, John

3. PATIENT'S BIRTH DATE (MM/DD/YY) 03/09/49

4. INSURED'S NAME (Last Name, First Name, Middle Initial) Doe, John

5. PATIENT'S ADDRESS (No., Street) 123 Main St.

6. PATIENT RELATIONSHIP TO INSURED Self ☒ Spouse ☐ Child ☐ Other ☐

7. INSURED'S ADDRESS (No., Street)

8. CITY New York

9. STATE NY

10. ZIP CODE 10001

11. TELEPHONE (Include Area Code) (212) 555-6789

12. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

13. IS PATIENT'S CONDITION RELATED TO:

14. IS PATIENT'S POLICY GROUP OR FECA NUMBER

15. INSURED'S DATE OF BIRTH (MM/DD/YY)

16. INSURED'S SEX (M/F)

17. OTHER CLAIM ID (Designated by NUCC)

18. INSURANCE PLAN NAME OR PROGRAM NAME

19. IS THERE ANOTHER HEALTH BENEFIT PLAN?

20. READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM. I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.

21. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE (SIGNED) _____

22. DATE _____

23. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) (MM/DD/YY)

24. OTHER DATE (MM/DD/YY)

25. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION (FROM/TO) (MM/DD/YY)

26. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES (FROM/TO) (MM/DD/YY)

27. OUTSIDE LAB? ☐ YES ☒ NO

28. \$ CHARGES

29. PRIOR AUTHORIZATION NUMBER

30. ORIGINAL REF. NO.

31. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY, BEGINNING AT service line below (24E) ICD 10d

32. A. DATE(S) OF SERVICE (MM/DD/YY) 10/01/20

33. B. PLACE OF SERVICE (EMG) 10

34. C. PROCEDURES, SERVICES, OR SUPPLIES (CPT/HCPCS) J9227

35. D. MODIFIER JW

36. E. DIAGNOSIS (ICD 10d) A

37. F. \$ CHARGES 85

38. G. DAYS (1-30)

39. H. FIRST PAY PERIOD

40. I. QUAL. NPI

41. J. RENDERING PROVIDER ID. #

42. 25. FEDERAL TAX ID. NUMBER

43. 26. PATIENT'S ACCOUNT NO.

44. 27. ACCEPT ASSIGNMENT? (For group contracts, see back)

45. 28. TOTAL CHARGE

46. 29. AMOUNT PAID

47. 30. Reserved for NUCC Use

48. 31. SIGNATURE OF PHYSICIAN OR SUPPLIER (I certify that the statements on the reverse apply to this bill and are made a part thereof.)

49. 32. SERVICE FACILITY LOCATION INFORMATION

50. 33. BILLING PROVIDER INFO & PH #

51. SIGNED _____

52. DATE _____

53. NPI _____

54. NPI _____

55. NUCC Instruction Manual available at: www.nucc.org

56. PLEASE PRINT OR TYPE

57. APPROVED OMB-0938-1197 FORM 1500 (02-12)

Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA (cont'd)

Hypersensitivity and Other Administration Reactions—SARCLISA ESCENA (cont'd)

Systemic Administration Reactions (cont'd)

To decrease the risk and severity of SARs, premedicate patients prior to SARCLISA ESCENA administration with leukotriene receptor antagonists (at cycle 1 only), acetaminophen, diphenhydramine or equivalent, and dexamethasone.

In case of grade 2 SAR during SARCLISA ESCENA administration, stop current administration and do not complete it. Administer additional premedication, as needed, for subsequent SARCLISA ESCENA administration. In case of grade 3 SAR during SARCLISA ESCENA administration, stop current administration and do not complete it. SARCLISA ESCENA administration may be resumed at the next planned administration. In case of a third occurrence of a grade 3 SAR, permanently discontinue SARCLISA ESCENA treatment. In case of grade 4 SAR, permanently discontinue SARCLISA ESCENA treatment.

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.

Your partners in navigating patient access and reimbursement

Our Case Managers are experts in navigating the oncology space. They'll provide the information you need to get your patients started on SARCLISA ESCENA and SARCLISA IV as quickly as possible.

SARCLISA[®]
(isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL

SARCLISA ESCENA[™]
(isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/70 mL

CirCLIO[®]
On-Body Delivery System

careASSIST[™]
Sanofi Support

SARCLISA[®]
(isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL

CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

CMS sample forms for SARCLISA (isatuximab-irfc) (cont'd)

The CMS UB-04 form is used for billing for prescribed medications administered in hospital outpatient settings. The notes below provide information about how to populate the essential fields that health plans require for reimbursement.

This sample claim form is intended for use only as a reference. Reimbursement codes are subject to continual change. Please confirm the accuracy of the codes you use to bill for the prescribed medications with each payer.

Form Locator (FL) 42

Enter the 4-digit revenue code that best describes the service provided, in accordance with hospital billing policy

FL 43

Enter the description of service (eg, IV therapy)

FL 44

Enter J-code J9227 and appropriate CPT codes

FL 46

Enter the appropriate number of service based on the HCPCS code dosage of 10 mg. For example, 10 mg = 1 billing unit; for a patient with MM weighing 85 kg, the dose would be 850 mg → 85 units

JW modifier: 850-mg dose would require one 500-mg and four 100-mg vials, for a total of 900 mg, resulting in 50-mg wastage. 50 mg = 5 billing units

FL 66

Enter the appropriate ICD-10-CM diagnosis codes for MM being treated

CMS-1450 (UB-04) sample⁸
Hospital outpatient form

Sample CMS-1450 (UB-04) form showing patient information, service details, and billing codes. The form includes fields for patient name, address, birth date, sex, and insurance information. It also contains a table for services provided, including SARCLISA (isatuximab-irfc) and IV therapy, with associated HCPCS and CPT codes. The form is marked with a large 'Sample' watermark.

Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA (cont'd)

Hypersensitivity and Other Administration Reactions—SARCLISA ESCENA (cont'd)

Injection Site Reactions

In clinical trials of SARCLISA ESCENA in combination with Pd, Kd, or VRd (IRAKLIA, IZALCO, and IsaSocut, respectively, N=411), injection site reactions (ISRs) with SARCLISA ESCENA administration were reported in 9% (8% Grade 1 and 1.5% Grade 2) of patients and in 0.86% of injections. Among the SARCLISA ESCENA injections with ISRs, 82% occurred the day of the administration and 4.2% were delayed by at least 3 days. With SARCLISA ESCENA + Pd and SARCLISA ESCENA + Kd, 5% of patients experienced symptoms of ISR (not collected in IsaSocut study). The most frequent (≥1%) symptoms of ISR were injection site erythema (3.3%), injection site swelling (2.1%), and injection site pain (1.5%).

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.

Your partners in navigating patient access and reimbursement

Our Case Managers are experts in navigating the oncology space. They'll provide the information you need to get your patients started on SARCLISA ESCENA and SARCLISA IV as quickly as possible.



CMS, Centers for Medicare & Medicaid Services; CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; IV, intravenous; MM, multiple myeloma.

Dose and infusion times for SARCLISA (isatuximab-irfc)⁹


Recommended Dosage

- **Relapsed or refractory multiple myeloma (RRMM):** 10 mg/kg actual body weight administered as an IV infusion in combination with Kd or Pd
- **Newly diagnosed multiple myeloma (NDMM):** 10 mg/kg actual body weight administered as an IV infusion in combination with VRd
- 250 mL fixed infusion volume
- Treatment is repeated until disease progression or unacceptable toxicity

Dosing Schedule

RRMM schedule:

Weekly dosing transitions to every other week after the first cycle. Treatment is administered in 28-day cycles.




On days when both SARCLISA and carfilzomib are administered, administer dexamethasone first, followed by SARCLISA infusion, then followed by carfilzomib infusion.


NDMM schedule:

Weekly dosing transitions to every other week after the first cycle and then to once monthly (every 4 weeks) at Cycle 18. After Cycle 4, bortezomib is stopped and patients receive triplet therapy with SARCLISA + Rd.

Induction treatment period: 4 induction cycles, 6 weeks per cycle*



Continuous treatment period: 4 weeks per cycle[†]



For dosing instructions for combination agents administered with SARCLISA, refer to the study design descriptions in the SARCLISA Prescribing Information and the respective manufacturer's Prescribing Information.

*Induction phase cycles=42 days each.

[†]Continuous phase cycles=28 days each.

Administration of SARCLISA (isatuximab-irfc)⁹

Premedication

Administer the following premedications prior to SARCLISA infusion to reduce the risk and severity of infusion-related reactions (IRRs).

Dexamethasone	When administered in combination with SARCLISA and carfilzomib: 20 mg (IV on the days of SARCLISA and/or carfilzomib infusions, PO on Day 22 in Cycle 2 and beyond, and PO on Day 23 in all cycles) When administered in combination with SARCLISA and pomalidomide: 40 mg PO or IV (or 20 mg PO or IV for patients ≥75 years of age) When administered in combination with SARCLISA, bortezomib, and lenalidomide: 20 mg (IV on the days of SARCLISA infusions, PO on the other days)
Acetaminophen	650 mg to 1,000 mg PO (or equivalent)
H₂ antagonists	Institution-preferred agent
Diphenhydramine	25 mg to 50 mg PO or IV (or equivalent). The IV route is preferred for at least the first 4 infusions

The above recommended dose of dexamethasone (PO or IV) corresponds to the total dose to be administered only once before infusion as part of the premedication and part of the backbone treatment. Administer dexamethasone before SARCLISA and pomalidomide, before SARCLISA and carfilzomib, and before SARCLISA, bortezomib, and lenalidomide administration.

Administer the recommended premedication agents 15 to 60 minutes prior to starting a SARCLISA infusion. No post-infusion medications are required for SARCLISA.

Infusion rates of SARCLISA administration

Infusion times decrease to 75 minutes after the second infusion in the absence of IRRs

Calculate the dose (mg) of required SARCLISA based on actual patient weight (measured prior to each cycle to have the administered dose adjusted accordingly). Note that more than 1 SARCLISA vial may be necessary to obtain the required dose for the patient.

Incremental escalation of the infusion rate should be considered only in the absence of IRRs.

	Dilution volume	Initial rate	Absence of IRR	Rate increment	Maximum rate	Total time (if no rate adjustments)
First infusion	250 mL	25 mL/h	For 60 min	25 mL/h every 30 min	150 mL/h	3 h 20 min
Second infusion	250 mL	50 mL/h	For 30 min	50 mL/h for 30 min, then increase by 100 mL/h	200 mL/h	1 h 53 min
Subsequent infusions	250 mL	200 mL/h	–	–	200 mL/h	75 min

SARCLISA should be administered by a healthcare professional, with immediate access to emergency equipment and appropriate medical support to manage IRRs if they occur.

IV, intravenous; Kd, carfilzomib and dexamethasone; PO, by mouth; Rd, lenalidomide and dexamethasone; VRd, bortezomib, lenalidomide, and dexamethasone.

Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA (cont'd)

Hypersensitivity and Other Administration Reactions—SARCLISA ESCENA (cont'd)

Injection Site Reactions (cont'd)

In case of grade 2 ISR during administration of SARCLISA ESCENA, interrupt it and resume it only after recovery to grade ≤1 with pauses during the administration (if using OBDS) or a slower administration (if manual injection). If the Grade 2 ISR occurs after the administration, continue SARCLISA ESCENA treatment after recovery to grade ≤1. In case of grade 3 or 4 ISR, permanently discontinue SARCLISA ESCENA treatment.

In case SARCLISA ESCENA administration using CirCLIQ OBDS needs to be paused, refer to the OBDS [Instructions for Use](#).

Please see Important Safety Information throughout and full Prescribing Information for SARCLISA and SARCLISA ESCENA.

Ordering SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™ and SARCLISA (isatuximab-irfc)

Specialty distributors

SARCLISA ESCENA with CirCLIQ and SARCLISA are available from the following authorized specialty distributors:

ASD Healthcare

1.800.746.6273
asdhealthcare.com
Part of AmerisourceBergen Specialty Distribution

McKesson Specialty Health

1.800.482.6700
mckesson.com/specialty/oncology

Cardinal Health Specialty Distribution

1.866.677.4844
specialtyonline.cardinalhealth.com

Morris & Dickson

1.800.388.3833
morrisdickson.com

McKesson Plasma and Biologics

1.877.625.2566
connect.mckesson.com

Oncology Supply

1.800.633.7555
oncologysupply.com
Part of AmerisourceBergen Specialty Distribution

Specialty pharmacies

SARCLISA ESCENA with CirCLIQ and SARCLISA are available for the dispensing process from the following authorized specialty pharmacies:

Biologics

1.800.850.4306
1.800.823.4506
biologics.mckesson.com

CVS Specialty

1.800.799.0251
1.855.296.0210
cvsspecialty.com

For additional details or product return inquiries, please contact your Sanofi Key Account Manager.

SARCLISA ESCENA™ (isatuximab-irfc) with CirCLIQ™ and SARCLISA® (isatuximab-irfc) patient support

Together, we can help patients at every step of their treatment journey

CareASSIST® is Sanofi's support program for patients prescribed SARCLISA ESCENA and SARCLISA. Once the patient is enrolled in CareASSIST, they're matched with a dedicated Case Manager. Case Managers are experts in the oncology access space and are deeply knowledgeable about the types of resources available to patients. They'll work with patients one-on-one to provide a tailored, personalized support experience.

Once enrolled in CareASSIST, patients will be paired with a Case Manager who will provide individualized guidance. Case Managers are trained to assist across the full spectrum of nonclinical support.

They will work closely with the patient to:



Want more information or additional resources?
Give one of our Case Managers a call at **1-833-WE+CARE (1-833-930-2273)**, Monday through Friday, 9 am to 6 pm ET.
You can also visit **SanofiCareASSIST.com** to learn more.



Guide patients through the insurance process and their benefits



Connect patients with resources that provide emotional, logistical, and health-related support



Help eligible patients with commercial insurance **pay as little as \$0*** out of pocket through the **CareASSIST Copay Program**



Support eligible patients who are uninsured or lack coverage receive their medication at no cost* through the **CareASSIST Patient Assistance Program**



Identify other financial assistance programs that may be able to help with treatment costs

***Important Notice:** Prescription must be for an approved indication. Not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs. Not valid where prohibited by law. This offer is nontransferable, limited to one per person, and cannot be combined with any other offer or discount. Any savings provided by the program may vary depending on patients' out-of-pocket costs. Sanofi reserves the right to modify or discontinue the program at any time without notice. All program details provided upon registration.

†Free product is provided by Sanofi Cares North America (SCNA), a charitable organization of Sanofi under Section 501(c)(3) of the IRC. DoD, US Department of Defense; VA, US Department of Veteran's Affairs.

Enroll your patient

Tap the button to activate personalized support from CareASSIST

SARCLISA
(isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL

SARCLISA ESCENA
(isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

CirCLIQ
On-Body Delivery System

careASSIST
Sanofi Support

Indications for SARCLISA (isatuximab-irfc) and SARCLISA ESCENA (isatuximab-irfc)

- SARCLISA and SARCLISA ESCENA are indicated in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)
- SARCLISA and SARCLISA ESCENA are indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy
- SARCLISA is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor
- SARCLISA ESCENA is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor

Important Safety Information for SARCLISA and SARCLISA ESCENA

CONTRAINDICATIONS—SARCLISA and SARCLISA ESCENA

SARCLISA and SARCLISA ESCENA are contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients.

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA

Infusion-Related Reactions—SARCLISA

SARCLISA can cause severe and/or serious infusion-related reactions including anaphylactic reactions. These reactions can be life-threatening and fatal outcomes have been reported. Severe signs and symptoms include cardiac arrest, hypertension, hypotension, bronchospasm, dyspnea, angioedema, and swelling.

In clinical trials (ICARIA-MM, IKEMA, and IMROZ), in patients treated with SARCLISA (N=592), infusion-related reactions occurred in 206 patients (35%). Among these 206 patients, 92% experienced infusion-related reactions during the first infusion and 12% after the first cycle.

The most common symptoms ($\geq 5\%$) of an infusion-related reaction included dyspnea and cough. Grade 1 infusion-related reactions were reported in 6% of patients, grade 2 in 28%, and grade 3 or 4 in 1.2%. Anaphylactic reactions occurred in less than 1% of patients. The total incidence of SARCLISA infusion interruptions was less than 1% and the incidence of patients with at least one SARCLISA infusion interruption due to infusion-related reactions was 26%. The median time to first SARCLISA infusion interruption was 61 minutes (range 4 to 240 minutes). SARCLISA was discontinued in 1% of patients due to infusion-related reactions. To decrease the risk and severity of IRRs, premedicate patients prior to SARCLISA infusion with acetaminophen, H_2 antagonists, diphenhydramine or equivalent, and dexamethasone.

Monitor vital signs frequently during the entire SARCLISA infusion. For patients with grade ≥ 2 reactions, interrupt SARCLISA infusion and provide appropriate medical management. For patients with grade 2 or grade 3 reactions, if symptoms improve to grade ≤ 1 , restart SARCLISA infusion at half of the initial infusion rate, with supportive care as needed, and closely monitor patients. If symptoms do not recur after 30 minutes, the infusion rate may be increased to the initial rate, and then increased incrementally. In case symptoms do not improve to grade ≤ 1 after interruption of SARCLISA infusion, persist or worsen despite appropriate medications, or require hospitalization, permanently discontinue SARCLISA and institute appropriate management. Permanently discontinue SARCLISA if an anaphylactic reaction or life-threatening (grade 4) IRR occurs and institute appropriate management.

Hypersensitivity and Other Administration Reactions—SARCLISA ESCENA

SARCLISA ESCENA can cause both systemic administration reactions (SARs), including severe or life-threatening reactions, and local injection-site reactions (ISRs).

Systemic Administration Reactions

In a pooled safety population of 411 patients with multiple myeloma who received SARCLISA ESCENA in combination with pomalidomide and dexamethasone (Pd); carfilzomib and dexamethasone (Kd); and bortezomib, lenalidomide, and dexamethasone (VRd) (IRAKLIA, IZALCO, and IsaSocut, respectively, N=411), SARs occurred in 3.2% (Grade 1: 2.2%, Grade 2: 0.7%, Grade 3: 0.2%) of patients. SARs occurred at the first administration in 1.9% of patients and at subsequent administrations in 1.5% of patients. The median time to onset was 4 hours (range: 12 minutes to 3 days). The most frequently reported symptoms of SARs (all below 1%) were pyrexia and dyspnea, and the most frequently reported Grade ≥ 3 symptom was dyspnea (not collected in IsaSocut study). In multiple myeloma clinical trials with intravenous isatuximab-irfc, anaphylactic reactions occurred in $<1\%$ of patients.

To decrease the risk and severity of SARs, premedicate patients prior to SARCLISA ESCENA administration with leukotriene receptor antagonists (at cycle 1 only), acetaminophen, diphenhydramine or equivalent, and dexamethasone.

In case of grade 2 SAR during SARCLISA ESCENA administration, stop current administration and do not complete it. Administer additional premedication, as needed, for subsequent SARCLISA ESCENA administration. In case of grade 3 SAR during SARCLISA ESCENA administration, stop current administration and do not complete it. SARCLISA ESCENA administration may be resumed at the next planned administration. In case of a third occurrence of a grade 3 SAR, permanently discontinue SARCLISA ESCENA treatment. In case of grade 4 SAR, permanently discontinue SARCLISA ESCENA treatment.

Injection Site Reactions

In clinical trials of SARCLISA ESCENA in combination with Pd, Kd, or VRd (IRAKLIA, IZALCO, and IsaSocut, respectively, N=411), injection site reactions (ISRs) with SARCLISA ESCENA administration were reported in 9% (8% Grade 1 and 1.5% Grade 2) of patients and in 0.86% of injections. Among the

SARCLISA ESCENA injections with ISRs, 82% occurred the day of the administration and 4.2% were delayed by at least 3 days. With SARCLISA ESCENA + Pd and SARCLISA ESCENA + Kd, 5% of patients experienced symptoms of ISR (not collected in IsaSocut study). The most frequent ($\geq 1\%$) symptoms of ISR were injection site erythema (3.3%), injection site swelling (2.1%), and injection site pain (1.5%).

In case of grade 2 ISR during administration of SARCLISA ESCENA, interrupt it and resume it only after recovery to grade ≤ 1 with pauses during the administration (if using OBDS) or a slower administration (if manual injection). If the Grade 2 ISR occurs after the administration, continue SARCLISA ESCENA treatment after recovery to grade ≤ 1 . In case of grade 3 or 4 ISR, permanently discontinue SARCLISA ESCENA treatment.

In case SARCLISA ESCENA administration using CirCLIQ OBDS needs to be paused, refer to the OBDS [Instructions for Use](#).

Infections—SARCLISA and SARCLISA ESCENA

SARCLISA and SARCLISA ESCENA can cause severe, life-threatening, or fatal infections.

In patients who received SARCLISA at the recommended dose in ICARIA-MM, IKEMA, and IMROZ (N=592), serious infections, including opportunistic infections, occurred in 46%, grade 3 or 4 infections occurred in 43%, and fatal infections occurred in 4.7%. The most common serious infection reported was pneumonia (32%).

In patients who received SARCLISA ESCENA subcutaneously in combination with Pd, Kd, or VRd (IRAKLIA, IZALCO, and IsaSocut, respectively, N=411), fatal infections occurred in 2.9% of patients, serious infections occurred in 29% of patients, and Grade ≥ 3 infections occurred in 29% of patients. The most commonly reported infections ($\geq 10\%$) were pneumonia (21%), upper respiratory tract infection (19%), and COVID-19 (12%). The most frequent serious infection ($\geq 5\%$) was pneumonia (17%).

Patients receiving SARCLISA or SARCLISA ESCENA should be closely monitored for signs and symptoms of infection prior to and during treatment and appropriate standard therapy instituted. Administer prophylactic antimicrobials according to guidelines. Antibacterial and antiviral prophylaxis (such as herpes zoster prophylaxis) should be considered during treatment.

Neutropenia—SARCLISA and SARCLISA ESCENA

SARCLISA may cause neutropenia.

In clinical trials (ICARIA-MM, IKEMA, and IMROZ), in patients treated with SARCLISA (N=592), neutropenia based on laboratory values occurred in 81%, with grade 3 or 4 occurring in 52%. Neutropenic infections occurred in 12% of patients, with grade 3 or 4 in 4.9%, and febrile neutropenia in 4%.

Neutropenia was reported in patients receiving SARCLISA ESCENA subcutaneously in combination with Pd, Kd, or VRd. In clinical trials of SARCLISA ESCENA (IRAKLIA, IZALCO, and IsaSocut, N=411), neutropenia occurred in 86% of patients

based on laboratory value. Grade 3–4 neutropenia occurred in 66% of patients based on laboratory value. Febrile neutropenia was reported in 3.4% and neutropenic infections occurred in 13% of patients.

Monitor complete blood cell counts periodically during treatment. If needed, use antibacterial and antiviral prophylaxis during treatment. Monitor patients with neutropenia for signs of infection. In case of grade 4 neutropenia, delay SARCLISA or delay or omit SARCLISA ESCENA dose until neutrophil count recovery to at least $1 \times 10^9/L$, and provide supportive care with growth factors, according to institutional guidelines. No dose reductions are recommended.

Second Primary Malignancies—SARCLISA and SARCLISA ESCENA

The incidence of second primary malignancies, during treatment and post-treatment, is increased in patients treated with SARCLISA-containing regimens. In clinical trials (ICARIA-MM, IKEMA, and IMROZ), in patients treated with SARCLISA (N=592), second primary malignancies occurred in 71 patients (12%).

In ICARIA-MM, at a median follow-up time of 52 months, second primary malignancies occurred in 7% of patients treated with SARCLISA, pomalidomide, and dexamethasone (Isa + Pd) and in 2% of patients treated with Pd.

In IKEMA study, at a median follow-up time of 57 months, second primary malignancies occurred in 10% of patients treated with SARCLISA, carfilzomib, and dexamethasone (Isa + Kd) and in 8% of patients treated with Kd.

In IMROZ study, at a median follow-up time of 60 months, second primary malignancies occurred in 16% of patients treated with SARCLISA, bortezomib, lenalidomide, and dexamethasone (Isa + VRd) and in 9% of patients treated with VRd.

The most common ($\geq 1\%$) second primary malignancies in ICARIA-MM, IKEMA, and IMROZ (N=592) included skin cancers (7% with SARCLISA-containing regimens and 3.1% with comparative regimens) and solid tumors other than skin cancer (4.6% with SARCLISA-containing regimens and 2.9% with comparative regimens). Patients with non-melanoma skin cancer continued treatment after resection of the skin cancer, except 2 patients in the Isa + VRd arm and 1 patient in the VRd arm of the IMROZ study.

Second primary malignancies were reported in 3.9% of patients in clinical trials with SARCLISA ESCENA in combination with Pd, Kd, and VRd (IRAKLIA, IZALCO, and IsaSocut, respectively, N=411).

Monitor patients for the development of second primary malignancies and initiate treatment as indicated.



Important Safety Information for SARCLISA and SARCLISA ESCENA (cont'd)

WARNINGS AND PRECAUTIONS—SARCLISA and SARCLISA ESCENA (cont'd)

Laboratory Test Interference

Interference with Serological Testing (Indirect Antiglobulin Test)

Isatuximab-irfc binds to CD38 on red blood cells (RBCs) and may result in a false-positive indirect antiglobulin test (indirect Coombs test). This interference with the indirect Coombs test may persist for at least 6 months after the last administration of intravenous isatuximab-irfc. The indirect antiglobulin test was positive during intravenous isatuximab-irfc + Pd treatment in 68% of the tested patients, and during intravenous isatuximab-irfc + Kd treatment in 63% of patients. In patients with a positive indirect antiglobulin test, blood transfusions were administered without evidence of hemolysis. ABO/RhD typing was not affected by intravenous isatuximab-irfc treatment.

Before the first isatuximab-irfc administration, conduct blood type and screen tests on isatuximab-treated patients. Consider phenotyping prior to starting isatuximab-irfc treatment. If treatment with isatuximab-irfc has already started, inform the blood bank that the patient is receiving isatuximab-irfc, and isatuximab-irfc interference with blood compatibility testing can be resolved using dithiothreitol-treated RBCs. If an emergency transfusion is required, non-cross-matched ABO/RhD-compatible RBCs can be given as per local blood bank practices.

Interference with Serum Protein Electrophoresis and Immunofixation Tests

Isatuximab-irfc is an IgG kappa monoclonal antibody that can be incidentally detected on both serum protein electrophoresis and immunofixation assays (IFE) used for the clinical monitoring of endogenous M-protein. This interference can impact the accuracy of the determination of complete response in some patients with IgG kappa myeloma protein. In patients with persistent very good partial response, where interference is suspected, consider using a validated isatuximab-specific IFE assay (Sebia Hydrashift) to remove isatuximab-irfc interference and specifically visualize any remaining serum M-protein, to facilitate determination of complete response.

Embryo-Fetal Toxicity—SARCLISA and SARCLISA ESCENA

Based on its mechanism of action, isatuximab-irfc can cause fetal harm when administered to a pregnant woman. Isatuximab-irfc may cause fetal immune cell depletion and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with isatuximab-irfc and for 7 months after the last dose. The combination of isatuximab-irfc with pomalidomide or lenalidomide is contraindicated in pregnant women because pomalidomide or lenalidomide may cause birth defects

and death of the unborn child. Refer to the pomalidomide or lenalidomide prescribing information on use during pregnancy.

ADVERSE REACTIONS—SARCLISA

In combination with pomalidomide and dexamethasone:

The most common adverse reactions (≥20%) were upper respiratory tract infection, infusion-related reactions, pneumonia, and diarrhea. The most common hematology laboratory abnormalities (≥80%) were decreased hemoglobin, decreased neutrophils, decreased lymphocytes, and decreased platelets.

In combination with carfilzomib and dexamethasone:

The most common adverse reactions (≥20%) were upper respiratory tract infection, infusion-related reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough, and back pain. The most common hematology laboratory abnormalities (≥80%) were decreased hemoglobin, decreased lymphocytes, and decreased platelets.

In combination with bortezomib, lenalidomide, and dexamethasone:

The most common adverse reactions (≥20%) were upper respiratory tract infections, diarrhea, fatigue, peripheral sensory neuropathy, pneumonia, musculoskeletal pain, cataract, constipation, peripheral edema, rash, infusion-related reaction, insomnia, and COVID-19. The most common hematologic laboratory abnormalities (≥80%) were decreased hemoglobin, decreased leukocytes, decreased lymphocytes, decreased platelets, and decreased neutrophils.

Serious adverse reactions occurred in 62% of patients receiving Isa-IV + Pd. Serious adverse reactions in >5% of patients who received Isa-IV + Pd included pneumonia (26%), upper respiratory tract infections (7%), and febrile neutropenia (7%). Fatal adverse reactions occurred in 11% of patients (those that occurred in more than 1% of patients were pneumonia and other infections [3%]).

Serious adverse reactions occurred in 59% of patients receiving Isa-IV + Kd. The most frequent serious adverse reactions in >5% of patients who received Isa-IV + Kd were pneumonia (25%) and upper respiratory tract infections (9%). Adverse reactions with a fatal outcome during treatment were reported in 3.4% of patients in the Isa-IV + Kd group (those occurring in more than 1% of patients were pneumonia occurring in 1.7% and cardiac failure in 1.1% of patients).

Serious adverse reactions occurred in 71% of patients receiving Isa-IV + VRd. The serious adverse reaction in >5% of patients who received Isa-IV + VRd was pneumonia (30%). Fatal adverse reactions occurred in 11% of patients with Isa-IV + VRd (those occurring in more than 1% of patients were pneumonia [5%]).

ADVERSE REACTIONS—SARCLISA ESCENA

In combination with pomalidomide and dexamethasone:

The most common adverse reactions (≥20%) are upper respiratory tract infection, fatigue, pneumonia, musculoskeletal pain, and diarrhea.

In combination with carfilzomib and dexamethasone:

The most common adverse reactions (≥20%) are upper respiratory tract infection and musculoskeletal pain.

In combination with bortezomib, lenalidomide, and dexamethasone:

The most common adverse reactions (≥20%) are peripheral neuropathy, constipation, diarrhea, fatigue, musculoskeletal pain, upper respiratory tract infections, injection site reaction, insomnia, edema, rash, and erythema.

The most common hematology laboratory abnormalities (≥40%) with SARCLISA ESCENA combination therapies are decreased neutrophils, decreased platelets, decreased hemoglobin, decreased leukocytes, and decreased lymphocytes.

Serious adverse reactions occurred in 53% of patients receiving SARCLISA ESCENA + Pd. Serious adverse reactions in ≥5% of patients who received SARCLISA ESCENA + Pd included pneumonia (20.5%). Fatal adverse reactions occurred in 4.9% of patients who received SARCLISA ESCENA + Pd, including pneumonia (1.5%), sepsis/septic shock (1.5%), death (0.8%), COVID-19, lower respiratory tract infection, hemorrhagic stroke, and sudden death (0.4% each).

Serious adverse reactions occurred in 41% of patients receiving SARCLISA ESCENA + Kd. Serious adverse reactions in ≥5% of patients included pneumonia (11%). Fatal adverse reactions occurred in 5.4% of patients who received SARCLISA ESCENA + Kd, including meningitis (1.4%), acute pulmonary edema (1.4%), acute respiratory distress syndrome (1.4%), and death from unknown cause (1.4%).

Serious adverse reactions occurred in 45% of patients who received SARCLISA ESCENA + VRd. Serious adverse reactions in >5% of patients included pneumonia (8%). Fatal adverse reactions occurred in 2.7% of patients who received SARCLISA ESCENA + VRd, including cardio-respiratory arrest (1.4%) and myocardial infarction (1.4%).

USE IN SPECIAL POPULATIONS—SARCLISA and SARCLISA ESCENA

Based on its mechanism of action, SARCLISA and SARCLISA ESCENA can cause fetal harm when administered to a pregnant woman. There are no available data on SARCLISA or SARCLISA ESCENA use in pregnant women to evaluate for a drug-associated risk.

The combination of SARCLISA or SARCLISA ESCENA and pomalidomide or lenalidomide is contraindicated in pregnant women because pomalidomide and lenalidomide may cause birth defects and death of the unborn child. Refer to the pomalidomide or lenalidomide prescribing information on use during pregnancy. Pomalidomide and lenalidomide are only available through a REMS program.

Because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during treatment and for 7 months after the last dose.

Please see accompanying full Prescribing Information for SARCLISA and SARCLISA ESCENA.



References: **1.** SARCLISA ESCENA [prescribing information]. Morristown, NJ: sanofi-aventis U.S. LLC. **2.** Centers for Medicare & Medicaid Services. Accessed March 13, 2026. <https://www.cms.gov/medicare/payment/medicare-advantage-rates-statistics/risk-adjustment/2026-model-software-icd-10-mappings> **3.** SEER. Accessed March 13, 2026. seer.cancer.gov/oncologytoolbox/canmed/hcpcs/1271/ **4.** American Medical Association. CPT® 2021 Professional Edition (Current Procedural Terminology). Chicago, IL: American Medical Association; 2020. **5.** Noridian Healthcare Solutions. Accessed March 17, 2026. <https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes> **6.** Centers for Medicare & Medicaid Services. Accessed March 13, 2026. www.cms.gov/medicare/coding-billing/place-of-service-codes/code-sets **7.** Centers for Medicare & Medicaid Services. Accessed January 13, 2026. <https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/Downloads/CMS1500.pdf> **8.** Centers for Medicare & Medicaid Services. Accessed January 13, 2026. <https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing-Items/CMS-1450> **9.** SARCLISA [prescribing information]. Morristown, NJ: sanofi-aventis U.S. LLC. **10.** Centers for Disease Control and Prevention. June 7, 2024. Accessed January 2, 2026. <https://www.cdc.gov/nchs/icd/icd-10-cm/index.html> **11.** Centers for Medicare & Medicaid Services. July 31, 2020. Accessed January 2, 2026. <https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-2-2020-drugs-and-biologicals-updated-07312020.pdf> **12.** Codify by AAPC. Accessed January 20, 2026. <https://www.aapc.com/codes/cpt-codes/96413> **13.** Codify by AAPC. Accessed January 20, 2026. <https://www.aapc.com/codes/cpt-codes/96415>

CPT © 2026 American Medical Association. All Rights Reserved. CPT® is a registered trademark of the American Medical Association.

All trademarks mentioned are the property of the Sanofi group except where trademarks are owned by third parties.

©2026 Sanofi. All rights reserved. MAT-US-2600384-v1.0-07/2026

sanofi


SARCLISA®
(isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL


SARCLISA ESCENA™
(isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE
WITH

CirCLIQ™
On-Body Delivery System